Slide 1: TUDRIQEV FDA Accelerated Approval Investor Call
August 6, 2026 TUDRIQEVTM (vusolimogene oderparepvec-wtpg) FDA Accelerated Approval Investor Call © 2026 Replimune Group Inc.
Slide 2: Safe Harbor
Safe Harbor Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements
Slide 3: Agenda
Agenda Introduction • Sushil Patel, PhD, CEO TUDRIQEVTM U.S. Prescribing Information • Kostas Xynos, MD, PhD, MBA, Chief Medical Officer U.S. Launch Plans • Sushil Patel, PhD, CEO Value and Milestones • Emily Hill, CFO Q&A Session TUDRIQEVTM Approval © 2026 Call Replimune © 2026 GroupInc. Replimune
Slide 4: © 2026 Replimune Group Inc.
© 2026 Replimune Group Inc.
Slide 5: FDA Approval Validates RPx Platform
FDA Approval Validates RPx Platform TUDRIQEV is First Oncolytic TUDRIQEV Replimune’s Viral Delivers Hope First Approved Combination for Advanced Product Therapy to Drive Melanoma Validating the Immune Patients RPx Platform Activation TUDRIQEVTM Approval Call © 2026 Replimune Inc. 5
Slide 6: TUDRIQEV is Now FDA Approved
TUDRIQEV (formerly known as RP1) is Now FDA Approved Approved in combination with nivolumab for the treatment of adults with unresectable advanced cutaneous melanoma who experience disease progression with a PD-1 blocking antibody- based regimen “Too-drih-kev” This indication is approved under accel
Slide 7: TUDRIQEV Label Reflects Broad Patient Population
TUDRIQEV Label Reflects Broad Patient Population Ability to treat superficial, Demonstrated effect in non- deep and visceral lesions, injected lesions in including lung, liver and other combination with nivolumab organs Patients can be retreated No requirement for prior BRAF based on physician discr
Slide 8: Overview of TUDRIQEV U.S. Prescribing Information
Overview of TUDRIQEV (vusolimogene oderparepvec-wtpg) U.S. Prescribing Information Kostas Xynos, Chief Medical Officer TUDRIQEVTM Approval © 2025 Call Replimune © 2026 GroupInc. Replimune Inc. 8
Slide 9: IGNYTE Study: Basis of Accelerated Approval of TUDRIQEV
IGNYTE Study: Basis of Accelerated Approval of TUDRIQEV Cycles 9-30+ Cycle 1 Cycles 2-8 Nivolumab Major efficacy outcome TUDRIQEV TUDRIQEV Nivolumab measures • Safety & tolerability • ORR • DOR + Additional cycles* TUDRIQEV 1x106 PFU/mL 1x107 PFU/mL (up to 10 mL) (up to 10 mL) Confirmed progression
Slide 10: Patient Demographics Reflect Real World Hard-to-Treat Population
Patient Demographics Reflect Real World Hard-to-Treat Population Demographics and Disease Characteristics N=91* Age, median, years (range) 62 (23, 91) Stage IV disease 80% Prior anti-PD1 adjuvant 13% No overall difference in Tumor PD-L1 expression negative 54% safety or effectiveness in Lung lesions
Slide 11: TUDRIQEV Prescribing Information Efficacy Summary
TUDRIQEV Prescribing Information Efficacy Summary Objective Response Rate by IRC N=91* ORR% (95% CI)a 24.2 (15.8, 34.3) Duration of Response (DoR)b N=91 Median DoR in months (95% CI)c 14.1 (10.7, NR) DoR range, months 3.9 to 34.6+ Patients with DoR > 6 months, n (%)d 86.1 Patients with DoR > 12 mont
Slide 12: Simple and Practical Dosing and Administration
Simple and Practical Dosing and Administration Highlights from Label • Simple dosing calculation for healthcare providers – 1mL/cm per tumor up to a max of 10mL per dose • Tumor selection flexibility – prioritize the most rapidly growing and largest new or existing lesions suitable for injection • S
Slide 13: TUDRIQEV Administration to Superficial Tumors
TUDRIQEV Administration to Superficial Tumors Injection Administration for Nonulcerated Superficial Tumors Injection Administration for Ulcerated Cutaneous Tumors TUDRIQEVTM Approval Call © 2026 Replimune Inc. 13
Slide 14: TUDRIQEV Injection for Deep or Visceral Tumors
TUDRIQEV Injection for Deep or Visceral Tumors including Lung, Kidney or other Organs Radial Injection Administration for Deep or Visceral Tumor Coaxial Injection Administration in Visceral Tumor with Image Guidance TUDRIQEVTM Approval Call © 2026 Replimune Inc. 14
Slide 15: Key TUDRIQEV Safety Highlights
Key TUDRIQEV Safety Highlights No Contraindications Warnings & Precautions No reported • Accidental exposure to TUDRIQEV, herpetic infection or reactivation, injection transmission procedure complications, immune-mediated events TUDRIQEV to close contacts Most common (>10%) adverse reactions • Nause
Slide 16: Confirmatory IGNYTE-3 Study: Enrollment On Track
Confirmatory IGNYTE-3 Study: Enrollment On Track Randomized 1:1 Advanced cutaneous melanoma RP1 + Nivolumab Progressed on anti-PD1 (n=200) AND anti-CTLA-4 OR not candidates for anti-CTLA-4 Treatment of Physician’s Choice (TPC*) (n=200) N=~400 Primary Analysis – OS Secondary Endpoints - PFS/ORR *Nivo
Slide 17: U.S. Launch Plans for TUDRIQEV
U.S. Launch Plans for TUDRIQEV Sushil Patel, PhD, CEO TUDRIQEVTM Approval © 2025 Call Replimune © 2026 GroupInc. Replimune Inc. 17
Slide 18: ~10K Addressable Patients Across Lines of Therapy
~10K Addressable Patients Across Lines of Therapy US Melanoma Patient Treatment Funnel Early PD-1 Containing Stage Surgery Only Regimens ~2K PD-1 Containing BRAF/ 1L Adj refractory Regimens1 MEK ~80% of patients who progress on PD-1 across lines of therapy are 2L ~7K No SOC* injectable (~10K address
Slide 19: Positioning TUDRIQEV to be the 1st Choice after PD-1 Progression
Positioning TUDRIQEV to be the 1st Choice after PD-1 Progression Compelling Instill data confidence in Ensure Deliver a TUDRIQEV to drive and favorable a positive TUDRIQEV meaningful TUDRIQEV targeted safety and rapid profile experience while value proposition adoption upon 1st creating a seamless s
Slide 20: Account Profiling Enabled Identification of Physician Champions
Account Profiling Enabled Identification of Physician Champions to Drive Rapid Adoption Early Adopter Accounts (n=~200) 94% 87% Medical Oncology IR champion champion identified identified Significant proactive requests for engagement immediately following approval California Texas Florida TUDRIQEVTM
Slide 21: Targeted Launch for Long-term Success
Targeted Launch for Long-term Success Early Adopters + Mod-High Volume Early Adopters ~1200 Accounts + High Volume ~450 Accounts Early Adopters ~200 Accounts ~6 Month Initial Focus Next 9-12 Months Longer-term TUDRIQEVTM Approval Call © 2026 Replimune Inc. 21
Slide 22: Today's Reimbursement Model Supports the Patient Treatment Journey
Today’s Reimbursement Model Supports the Patient Treatment Journey Extensive payer Existing Reimbursement engagement procedural codes landscape reaching nearly 80% of to support TUDRIQEV supports adoption of covered lives anticipated injections by IRs and TUDRIQEV in to expedite formulary med oncs c
Slide 23: Patient Treatment Journey Aligned with Approved Product Label
Patient Treatment Journey Aligned with Approved Product Label Patient progresses on PD-1 and TUDRIQEV & Nivo TUDRIQEV is treatment visits are chosen as the scheduled Q2 next therapy weeks TUDRIQEV injections in outpatient Oncologist and IR can setting with standard collaborate to create cleaning pro
Slide 24: Comprehensive Patient Support Program Planned
Comprehensive Patient Support Program Planned Patient and provider services in place to support a positive treatment experience TUDRIQEVTM Approval Call © 2026 Replimune Inc. 24
Slide 25: Value and Milestones
Value and Milestones Emily Hill, Chief Financial Officer TUDRIQEVTM Approval © 2025 Call Replimune © 2026 GroupInc. Replimune Inc. 25
Slide 26: Pillars to Drive Long-Term Value
Pillars to Drive Long-Term Value U.S. based 63,000 square foot state-of- the-art manufacturing TUDRIQEV expected to ship in facility to support global approximately 60 days commercial supply Cost of treatment in line with Delivering value and comparable treatments in advanced achieving broad coverag
Slide 27: The Future of the RPx Platform
The Future of the RPx Platform Clinical trials & indication IND/CTA Phase 1/2 Phase 2 Registration-Directed Approved RP1 Engineered HSV backbone + GM-CSF + GALV-GP R- Melanoma PDUFA date July 22, 2025 IGNYTE* + nivolumab (anti-PD1 failed) IGNYTE-3 Melanoma + nivolumab (anti-PD1 failed) Randomized Co
Slide 28: Anticipated Milestones in the Next 6 Months
Anticipated Milestones in the Next 6 Months Pipeline RP2 Uveal Expansion TUDRIQEV Preliminary into First Melanoma RP2 Additional Revenue Ph 2/3 HCC/BTC Solid Reporting Study Data Tumors Transition TUDRIQEVTM Approval Call © 2026 Replimune Inc. 28
Slide 29: Q&A
Q&A TUDRIQEVTM TM TUDRIQEV Approval Approval Call Call ©© 2026 2026 Replimune Replimune Inc. Inc. 29
Slide 30: Thank You
TUDRIQEV Approval Call August 6, 2026 Thank You © 2025 Replimune Group Inc.